Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683655 | 1.00 | HTR2B (0.49) | HTR2BGPR35DRD2DRD4DRD3 | |
| SCHEMBL4415767 | 1.00 | HTR2B (0.49) | HTR2BGPR35DRD2DRD4DRD3 | |
| SCHEMBL14384029 | 0.86 | HTR2B (0.47) | HTR2BGPR35DRD2DRD4DRD3 | |
| SCHEMBL12872412 | 0.86 | GPR35 (0.56) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL10425856 | 0.86 | MAPT (0.52) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL9231796 | 0.86 | GPR35 (0.56) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL5494654 | 0.85 | GPR35 (0.45) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL5493591 | 0.85 | MAPT (0.46) | HTR2BGPR35MAPTTSHRALOX15 | |
| SCHEMBL31022773 | 0.84 | MKNK1 (0.46) | HTR2BGPR35 | |
| SCHEMBL12316835 | 0.84 | MKNK1 (0.46) | HTR2BGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290434-A | Spiropiperidine derivative containing alpha-methylene-gamma-butyrolactone, preparation method and application thereof | 南开大学 | 2024-07-05 | — | — | CN | claimed |
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | EMPRESS THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118290434-A | Spiropiperidine derivative containing alpha-methylene-gamma-butyrolactone, preparation method and application thereof | 南开大学 | 2024-07-05 | — | — | CN | disclosed |
| CN-110759873-B | 4, 5-dihydrothiazole carboxylic acid derivatives containing sulfonyl hydrazine structure, and preparation method and application thereof | 天津中医药大学 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023192388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3289876-B1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-6878828-B2 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | GENZYME CORPORATION (US) | 2005-04-12 | — | — | US | disclosed |
| US-6861532-B2 | Synthesis of 2-alkylcysteine | GENZYME CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-6794515-B2 | CONDENSING CYSTEINE WITH CABOCYCLIC NITRILES TO FORM 2-ARYLTHIAZOLINE-4-CARBOXYLIC ACID, THEN AMIDATION, ALKYLATION, HYDROLYZING AND OPTIONALLY PURIFYING TO FORM 2-METHYLCYSTEINE | GENZYME CORPORATION | 2004-09-21 | — | — | US | disclosed |
| US-20030236435-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | GENZYME CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-20030236434-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline amide | GENZYME CORPORATION (US) | 2003-12-25 | — | — | US | disclosed |
| US-20030229231-A1 | Synthesis of 2-alkylcysteine | GENZYME CORPORATION | 2003-12-11 | — | — | US | disclosed |
| US-20030225287-A1 | Synthesis of chiral 2-alkyl amino acids | GENZYME CORPORATION | 2003-12-04 | — | — | US | disclosed |
| WO-2003097622-A2 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | GENZYME CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030088105-A1 | Process for the preparation of substituted thiazolines and their intermediates | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2003-05-08 | — | — | US | disclosed |
| EP-1302467-A2 | Process for the preparation of substituted thiazoline derivatives and their intermediate | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | HTR2B 4622/4885GPR35 2364/4885DRD2 4550/4885 |
| US-20030225287-A1 | Synthesis of chiral 2-alkyl amino acids | FTH1, CISD2, PTMS | HTR2B 3583/4885GPR35 4458/4885DRD2 1311/4885 |
| US-20030236435-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | FTH1, TFRC, CNDP2 | HTR2B 2843/4885GPR35 3841/4885DRD2 443/4885 |
| US-20030229231-A1 | Synthesis of 2-alkylcysteine | FTH1, CISD2, CNDP2 | HTR2B 3393/4885GPR35 4273/4885DRD2 1760/4885 |
| US-20030088105-A1 | Process for the preparation of substituted thiazolines and their intermediates | CBR1, RCOR1, MT-CO1 | HTR2B 1051/4885GPR35 4478/4885DRD2 1284/4885 |
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | SI, VIP, APC | HTR2B 2431/4885GPR35 1704/4885DRD2 494/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HTR2B 4622/4885GPR35 2364/4885DRD2 4550/4885 |
| US-20030236434-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline amide | CNDP2, FTH1, PTMS | HTR2B 3232/4885GPR35 3918/4885DRD2 1117/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HTR2B 4622/4885GPR35 2364/4885DRD2 4550/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | HTR2B 4622/4885GPR35 2364/4885DRD2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.